Literature DB >> 26430077

Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test.

Anita Y H Lee1, Derek L Chappell1, Monika J Bak2, Michael Judo3, Linda Liang3, Tatyana Churakova3, Gulesi Ayanoglu3, Jose Castro-Perez4, Haihong Zhou4, Stephen Previs4, Sandra C Souza4, Michael E Lassman5, Omar F Laterza1.   

Abstract

BACKGROUND: Proglucagon-derived peptides (PGDPs), which include glucagon-like peptide (GLP)-1, glucagon, and oxyntomodulin, are key regulators of glucose homeostasis and satiety. These peptide hormones are typically measured with immuno-based assays (e.g., ELISA, RIA), which often suffer from issues of selectivity.
METHODS: We developed a multiplexed assay for measuring PGDPs including GLP-1 (7-36) amide, GLP-1 (9-36) amide, glucagon, and oxyntomodulin by mass spectrometry and used this assay to examine the effect of a meal tolerance test on circulating concentrations of these hormones. Participants fasted overnight and were either given a meal (n = 8) or continued to fast (n = 4), with multiple blood collections over the course of 3 h. Plasma samples were analyzed by microflow immunoaffinity (IA)-LC-MS/MS with an isotope dilution strategy.
RESULTS: Assay performance characteristics were examined and established during analytical validation for all peptides. Intra- and interassay imprecision were found to be 2.2%-10.7% and 6.8%-22.5%, respectively. Spike recovery was >76%, and dilution linearity was established up to a 16-fold dilution. Immediately after the meal tolerance test, GLP-1 and oxyntomodulin concentrations increased and had an almost identical temporal relationship, and glucagon concentrations increased with a slight delay.
CONCLUSIONS: IA-LC-MS/MS was used for the simultaneous and selective measurement of PGDPs. This work includes the first indication of the physiological concentrations and modulation of oxyntomodulin after a meal.
© 2015 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26430077     DOI: 10.1373/clinchem.2015.244251

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

Review 1.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

2.  Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma.

Authors:  Nicolai J Wewer Albrechtsen; Daniel Hornburg; Reidar Albrechtsen; Berit Svendsen; Signe Toräng; Sara L Jepsen; Rune E Kuhre; Marie Hansen; Charlotte Janus; Andrea Floyd; Asger Lund; Tina Vilsbøll; Filip K Knop; Henrik Vestergaard; Carolyn F Deacon; Felix Meissner; Matthias Mann; Jens J Holst; Bolette Hartmann
Journal:  EBioMedicine       Date:  2016-03-31       Impact factor: 8.143

Review 3.  Methods and Guidelines for Measurement of Glucagon in Plasma.

Authors:  Jens J Holst; Nicolai J Wewer Albrechtsen
Journal:  Int J Mol Sci       Date:  2019-10-30       Impact factor: 5.923

4.  In vitro metabolism of synthetic Elabela/Toddler (ELA-32) peptide in human plasma and kidney homogenates analyzed with mass spectrometry and validation of endogenous peptide quantification in tissues by ELISA.

Authors:  Duuamene Nyimanu; Richard G Kay; Rhoda E Kuc; Alastair J H Brown; Fiona M Gribble; Janet J Maguire; Anthony P Davenport
Journal:  Peptides       Date:  2021-08-26       Impact factor: 3.750

5.  Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion.

Authors:  Nicolai J Wewer Albrechtsen; Simon Veedfald; Astrid Plamboeck; Carolyn F Deacon; Bolette Hartmann; Filip K Knop; Tina Vilsboll; Jens J Holst
Journal:  J Diabetes Res       Date:  2015-12-29       Impact factor: 4.011

6.  GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.

Authors:  Michele J Pachanski; Melissa E Kirkland; Daniel T Kosinski; Joel Mane; Boonlert Cheewatrakoolpong; Jiyan Xue; Daphne Szeto; Gail Forrest; Corin Miller; Michelle Bunzel; Christopher W Plummer; Harry R Chobanian; Michael W Miller; Sarah Souza; Brande S Thomas-Fowlkes; Aimie M Ogawa; Adam B Weinglass; Jerry Di Salvo; Xiaoyan Li; Yue Feng; Daniel A Tatosian; Andrew D Howard; Steven L Colletti; Maria E Trujillo
Journal:  PLoS One       Date:  2017-10-20       Impact factor: 3.240

7.  Liquid chromatography/mass spectrometry based detection and semi-quantitative analysis of INSL5 in human and murine tissues.

Authors:  R G Kay; S Galvin; P Larraufie; F Reimann; F M Gribble
Journal:  Rapid Commun Mass Spectrom       Date:  2017-12-15       Impact factor: 2.419

8.  Quantitative mass spectrometry for human melanocortin peptides in vitro and in vivo suggests prominent roles for β-MSH and desacetyl α-MSH in energy homeostasis.

Authors:  Peter Kirwan; Richard G Kay; Bas Brouwers; Vicente Herranz-Pérez; Magdalena Jura; Pierre Larraufie; Julie Jerber; Jason Pembroke; Theresa Bartels; Anne White; Fiona M Gribble; Frank Reimann; I Sadaf Farooqi; Stephen O'Rahilly; Florian T Merkle
Journal:  Mol Metab       Date:  2018-08-21       Impact factor: 7.422

9.  The plasma peptides of ovarian cancer.

Authors:  Jaimie Dufresne; Pete Bowden; Thanusi Thavarajah; Angelique Florentinus-Mefailoski; Zhuo Zhen Chen; Monika Tucholska; Tenzin Norzin; Margaret Truc Ho; Morla Phan; Nargiz Mohamed; Amir Ravandi; Eric Stanton; Arthur S Slutsky; Claudia C Dos Santos; Alexander Romaschin; John C Marshall; Christina Addison; Shawn Malone; Daren Heyland; Philip Scheltens; Joep Killestein; Charlotte E Teunissen; Eleftherios P Diamandis; K W Michael Siu; John G Marshall
Journal:  Clin Proteomics       Date:  2018-12-21       Impact factor: 3.988

10.  Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

Authors:  Francis S Willard; Jonathan D Douros; Maria Bn Gabe; Aaron D Showalter; David B Wainscott; Todd M Suter; Megan E Capozzi; Wijnand Jc van der Velden; Cynthia Stutsman; Guemalli R Cardona; Shweta Urva; Paul J Emmerson; Jens J Holst; David A D'Alessio; Matthew P Coghlan; Mette M Rosenkilde; Jonathan E Campbell; Kyle W Sloop
Journal:  JCI Insight       Date:  2020-09-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.